Context: Type 2 deiodinase (D2) converts T4 in T3 in several human tissues, including hypothalamus and pituitary, and, therefore, plays a pivotal role in the negative feedback regulation of TSH secretion. A common variant of the gene, threonine (Thr) 92 alanine (Ala), has been identified and associated with decreased D2 enzymatic activity. Objective: Our objective was to investigate whether this polymorphism predicts the T 4 dosage needed to obtain target TSH levels in thyroidectomized patients. Setting: Ambulatory patients were included in the study. Patients: A total of 191 consecutive thyroid cancer patients, previously treated by near total thyroidectomy and radioiodine ablation, were studied. They were on stable T4 dose treatment aimed at obtaining either suppressed (supp) (n = 117, <0.1 mU/liter) or near-supp (n = 74, ≥ 0.1 <0.5 mU/liter) serum TSH levels. Main Outcome Measures: DNA genotyping for D2 Thr92Ala variant and evaluation of T4 dose (μg/kg) needed to obtain target TSH levels were determined. Results: Ala/Ala homozygous patients needed a higher T 4 dose as compared with patients carrying the Thr92 variant (X/Thr patients) according to a recessive genetic model (2.08 ± 0.43 vs. 1.90 ± 0.35 μg/kg; P <0.05). This difference was observable in the near-supp group (P = 0.002), but not in the supp group (P = 0.4). Conclusions: D2 Thr92Ala polymorphism seems to predict the need for higher T4 intake in thyroidectomized patients. If this finding is confirmed in additional studies, it may predict the T4 requirement to suppress TSH on the basis of the individual genetic background.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism